Platelet Aggregation Inhibitors Clinical Trial
Official title:
MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)
The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12 months from coronary stent implantation. It seeks to determine if initiation of a prolonged cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and whether a cangrelor infusion before cardiac and non cardiac procedures is safe.
This will be a randomized, double-blind, placebo-controlled study enrolling patients with
coronary stent, still on DAPT, undergoing cardiac and non cardiac surgery within 12 months
from coronary stent implantation.
The MONET BRIDGE study is designed to assess the use of cangrelor as a platelet-inhibiting
bridge for patients who discontinue DAPT before cardiac and non cardiac surgery within 12
months from coronary stent implantation. It seeks to determine if initiation of a prolonged
cangrelor infusion maintains effective platelet inhibition after discontinuation of P2Y12 and
whether a cangrelor infusion before cardiac and non cardiac procedures is safe.
The primary efficacy objective of this study is to demonstrate that a cangrelor infusion will
maintain levels of residual platelet reactivity (PRU < 208) as measured by Accriva VerifyNow®
P2Y12 assay.
The main safety objective is to demonstrate that patients receiving cangrelor infusion before
cardiac and non cardiac surgery have an acceptable safety profile and can undergo surgery
without excessive bleeding peri-operatively.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
| Recruiting |
NCT04796714 -
AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE
|
Phase 4 | |
| Completed |
NCT02711410 -
The Influence of CYP2C19 Polymorphism and Clinical Outcomes in Stroke Patients
|
N/A | |
| Completed |
NCT05278637 -
GM03 - Platelet RNA Signatures of Aspirin
|
Early Phase 1 | |
| Recruiting |
NCT03288441 -
Management and Outcomes of Anti-thrombotic Medication Use in Thrombocytopenia
|
||
| Recruiting |
NCT05306951 -
Correct Timing of Head Imaging in Trauma
|
||
| Recruiting |
NCT05732701 -
Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions
|
N/A | |
| Recruiting |
NCT05702463 -
Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II
|
Phase 1 | |
| Completed |
NCT01354808 -
ACCEL-LOADING-ACS Study
|
Phase 4 | |
| Completed |
NCT00799396 -
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)
|
Phase 4 | |
| Completed |
NCT00325390 -
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
|
Phase 3 | |
| Completed |
NCT04999293 -
Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention
|
||
| Completed |
NCT04328883 -
Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin
|
Phase 1 | |
| Completed |
NCT02808767 -
Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction
|
Phase 4 | |
| Completed |
NCT00769938 -
WOEST ( What is the Optimal antiplatElet & Anticoagulant Therapy in Patients With Oral Anticoagulation and Coronary StenTing)
|
Phase 4 | |
| Completed |
NCT03599284 -
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
|
Phase 2 | |
| Completed |
NCT03785509 -
The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients
|
||
| Unknown status |
NCT01103843 -
Plavix, Prasugrel and Drug Eluting Stents Pilot Trial
|
N/A | |
| Active, not recruiting |
NCT03462498 -
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
|
Phase 4 |